Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionUniversal- Beteiligungs- und Servicegesellschaft mbH
Latest Disclosed Ownership73,737 shares
Latest Disclosed Value $ 2,317,554
Universal- Beteiligungs- und Servicegesellschaft mbH reports 48.20% decrease in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On August 6, 2026 - Universal- Beteiligungs- und Servicegesellschaft mbH filed a 13F-HR form disclosing ownership of 73,737 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $2,317,554 USD as of June 30, 2026. The entity filed a previous 13F-HR on May 11, 2026 disclosing 142,361 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of -48.20% during the quarter. The current value of the position is $2,321,978 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-08-06 2026-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 73,737 -68,624 -48.20 2,318 -34.25 0.0035
2026-05-11 2026-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 142,361 -25,402 -15.14 3,525 -9.94 0.0061
2026-01-28 2025-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 167,763 38,695 29.98 3,913 53.93 0.0064
2025-10-30 2025-09-30 13F CATALYST PHARMACEUTICALS COM 14888U101 129,068 -16,594 -11.39 2,543 -19.56 0.0042
2025-08-11 2025-06-30 13F CATALYST PHARMACEUTICALS COM 14888U101 145,662 -25,174 -14.74 3,161 -23.71 0.0056
2025-05-06 2025-03-31 13F CATALYST PHARMACEUTICALS COM 14888U101 170,836 -8,014 -4.48 4,143 10.99 0.0083
2025-02-28 2024-12-31 13F CATALYST PHARMACEUTICALS COM 14888U101 178,850 178,850 3,733 0.0074
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.